long intergenic non-protein coding RNA 1842Genealiases: []
Q-omics provides the consensus-scored LINC01842 profile across patient tissues and cancer cell-line models. LINC01842 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC01842 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, LINC01842 RNA expression shows 10,669 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight UVM, HNSC, and SARC as cancer lineages where LINC01842 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01842 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01842 survival associations across molecular data types. LINC01842 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01842 RNA expression–survival associations across cancer types. High LINC01842 expression shows unfavorable associations in UVM, LGG, ACC, BLCA, KIRP and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC01842 RNA expression.
This table summarizes LINC01842 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01842. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01842 shows higher tumor expression in HNSC, KIRC, LUAD, LUSC, BRCA and UCEC. The HNSC box plot shows higher LINC01842 RNA expression in tumor versus normal tissue (log2 FC = +1.108, t-test p < 0.001).
This table shows molecular features associated with LINC01842 in patient tissues and cancer cell lines. In patient samples, LINC01842 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
